Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

S. Ederhy; A. Hollebecque; N. Haddour; C. Massard; G. Fleury; C. Ferte; S. Adavane; B. Besse; F. Boccara; J. C. Soria; A. Cohen

doi:10.1016/j.rmr.2013.09.021

Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

S. Ederhy, A. Hollebecque, N. Haddour, C. Massard, G. Fleury, C. Ferte, S. Adavane, B. Besse, F. Boccara, J. C. Soria, A. Cohen

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

Titre traduit de la contribution	Management of the cardiovascular complications of treatment in thoracic oncology
langue originale	Français
Numéro d'article	810
Pages (de - à)	173-180
Nombre de pages	8
journal	Revue des Maladies Respiratoires
Volume	31
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.rmr.2013.09.021
état	Publié - 1 janv. 2014

mots-clés

Anti-angiogenic
Arterialhypertension
Chemotherapy
Congestive heartfailure

Accès au document

10.1016/j.rmr.2013.09.021

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d824c8c07c4149d2a90d1cfe1e2ea29b,

title = "Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique",

abstract = "The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.",

keywords = "Anti-angiogenic, Arterialhypertension, Chemotherapy, Congestive heartfailure",

author = "S. Ederhy and A. Hollebecque and N. Haddour and C. Massard and G. Fleury and C. Ferte and S. Adavane and B. Besse and F. Boccara and Soria, {J. C.} and A. Cohen",

year = "2014",

month = jan,

day = "1",

doi = "10.1016/j.rmr.2013.09.021",

language = "Fran{\c c}ais",

volume = "31",

pages = "173--180",

journal = "Revue des Maladies Respiratoires",

issn = "0761-8425",

number = "2",

}

TY - JOUR

T1 - Prise en charge des complications cardiovasculaires des traitements en oncologie thoracique

AU - Ederhy, S.

AU - Hollebecque, A.

AU - Haddour, N.

AU - Massard, C.

AU - Fleury, G.

AU - Ferte, C.

AU - Adavane, S.

AU - Besse, B.

AU - Boccara, F.

AU - Soria, J. C.

AU - Cohen, A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

AB - The management of patients suffering from bronchial and lung tumors depends on conventional chemotherapy and/or targeted molecular therapies. The prescription of these chemotherapies may be accompanied by cardiovascular complications, principally congestive heart failure, arterial hypertension and arterial or venous thrombo-embolism, the frequency of which varies with the molecule administered. The management of these complications is currently poorly standardized and should take account of the patient's oncological prognosis.

KW - Anti-angiogenic

KW - Arterialhypertension

KW - Chemotherapy

KW - Congestive heartfailure

UR - http://www.scopus.com/inward/record.url?scp=84900809195&partnerID=8YFLogxK

U2 - 10.1016/j.rmr.2013.09.021

DO - 10.1016/j.rmr.2013.09.021

M3 - Article

C2 - 24602684

AN - SCOPUS:84900809195

SN - 0761-8425

VL - 31

SP - 173

EP - 180

JO - Revue des Maladies Respiratoires

JF - Revue des Maladies Respiratoires

IS - 2

M1 - 810

ER -